Effect of candesartan on mean systemic blood pressure and pulmonary artery pressure levels in patients undergoing hemodialysis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. to estimate ability of candesartan to decrease mean systemic blood pressure (bp) and pulmonary artery pressure (pap) levels among patients on maintaining hemodialysis. material and methods. to perform prospective survey, 30 patients were randomized into two groups, taking candesartan and usual hypotensive drugs. results. at the end of study in patients that took angiotensin receptor blocker mean systemic bp and mean pap decline was registered (from 104,7±12,3 to 97,8±10,4 mm hg; P=0,03 and from 27 (26,4-32,5) to 22,7 (20,3-28,2) MM hg; p=0,02 respectively). in group which subjects received standard hypotensive drugs mean systemic bp and mean pap didn’t changed (100,2±ii and 101,3±12,i mm hg; p=0,58, and 29,5 (26,4-38,6) and 26,4 (23,4-31,3) mm hg; p=o,ii accordingly). adverse reactions as potassium and creatinine serum elevation were not registered (4,7±o,72 and 4,8±o,61 mmol/l; p=o,52, 749±143 and 749±131 MCMOL/L; P=0,98, RESPECTIVELY). Conclusion. Candesartan showed it’s efficacy and safety in lowering systemic bp and pap that elevated levels are predictors of unfavorable outcomes.

Full Text

Restricted Access

About the authors

Kanatbek S. Dzheentaev

«Artificial kidney» unit, National center of cardiology and internal medicine named after Mirsaid Mirrakhimov

Email: jeen81@mail.ru
Nephrologist of the artificial kidney department Bishkek city, Kyrgyzstan

Rysbek R. Kaliev

I.K. Akhunbaev Kyrgyz State Medical Academy, chair of internal diseases

Email: karys2002@mail.ru
Doctor of Medical Sciences, Professor at the Department Chair of Internal Diseases Bishkek city, Kyrgyzstan

References

  1. Hypertension, by DOPPS Country and Cross-Section. 2006. http://www. dopps.org/annualreport/html/MCOMHTN. http://www.dopps.org/annual report/html/MCOMHTN
  2. Agarwal R., Nissenson A.R., Batlle D., et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med. 2003;115:291-297.
  3. Salem M.M. Hypertension in the hemodialysis population: a survey of 649 patients. Am. J. Kidney Dis. 1995;26:461-468.
  4. Rahman M, Dixit A., Donley V., st al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am. J. Kidney Dis. 1999;33:498-506.
  5. Klassen P.S., Lowrie E.G., Reddan D.N., et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548-1555.
  6. Кутырина И.М., Лифшиц Н.Л. Роль ренин-ангиотензин-альдосте-роновой системы в патогенезе артериальной гипертензии при хронической почечной недостаточности. Тер. архив. 1999;71(6):64-67.
  7. Bolignano D., Rasteli S., Agarwal R., et al. Pulmonary hypertension in CKD. Am. J. Kidney Dis. 2013;61(4):612-622.
  8. Tang M., Batty J.A., Lin C. Pulmonary Hypertension, Mortality, and Cardiovascular Disease in CKD and ESRD Patients: A Systematic Review and Meta-analysis. Am. J. Kidney Dis. 2018;72(1):75-83.
  9. Chawla L.S., Herzog C.A. Costanzo M.R., et al. Proposal for a Functional Classification System of Heart Failure in Patients With End-Stage Renal Disease: Proceedings of the Acute Dialysis Quality Initiative (ADQI) XI Workgroup. J. Am. Coll. Cardiol. 2014;63(13):1246-1252.
  10. Husain A., Azim S., Mitra M., et al. A Review on Candesartan: Pharmacological and Pharmaceutical Profile. J. Appl. Pharmaceut. Sci. 2011;01(10):12-17.
  11. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction Results of the CHARM Low-Left Ventricular Ejection Fraction Trials. Circulation. 2004;110:2618-2626.
  12. Schulz E.G., Bahri S., Schettler V., et al. Pharmacokinetics and antihypertensive effects of candesartan cilexetil in patients undergoing haemodialysis: an open-label, single-centre study. Clin. Drug Investig. 2009;29(11):713-719.
  13. Suzuki H., Kanno Y., Sugahara S., et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-labelrandomized controlled trial. Am. J. Kidney Dis. 2008;52(3):501-506
  14. Morimoto S., Ogihara T. TCV-116: A New Angiotensin Receptor Antagonist I1 Type-1. Cardiovasc. Drug Rev. 1994;12(2):153-164.
  15. Калиев Р.Р., Джеентаев К.Ш., Ратушная Н.А. Особенности клинической картины легочной гипертензии у пациентов с терминальной стадией хронической почечной недостаточности, находящихся на хроническом программном гемодиализе. Вестник Кыргызско-российского славянского университета. 2014;14(4):86-90.
  16. Li Z, Liu S., Liang X., et al. Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients. Int. Urol. Nephrol. 2014;46(1):141-149. https://doi.org/10.1007/s11255-013-0486-z
  17. Pabst S., Hammerstingl C., Hundt F., et al. Pulmonary Hypertension in Patients with Chronic Kidney Disease on Dialysis and without Dialysis: Results of the PEPPER-Study. PLoS. One. 2012;7(4). doi: 10.1371/journal. pone.0035310.
  18. Li-Ya Yang, Xiao Ge, Yan-Li Wang, et al. Angiotensin Receptor Blockers Reduce Left Ventricular Hypertrophy in Dialysis Patients: A Meta-Analysis. Am. J. Med. Sci. 2013;345(1):1-9.
  19. Мухаматулина Д.М., Гизатулина Т.П., Шалаев С.В. Эффективность блокатора ангиотензина кандесартана в терапии хронической сердечной недостаточности. IIнациональный конгресс терапевтов. М., 2007. 159 с.
  20. Morrell N.W., Higham M.A., Phillips P.G., et al. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir. Res. 2005;6(1):88.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies